16th Annual Anglonordic Life Science Conference
Anglonordic is the only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. With an established format of panel discussions, parallel technology and biotech investment rooms, plus 1:1 meetings, this 1-day London conference provides exceptional value. Investors with funds attend free-of-charge.
MEET decision makers at leading and upcoming drug discovery and technology companies from the UK and Nordic regions, along with investment firms from throughout Europe
LEARN from major investment firms about the current status of European investment in life science technologies
GAIN insights from experienced life science operators within the Anglo-Nordic space
The Anglonordic Life Science Conference has a “by-invitation-only” policy. The organisers welcome a limited number of service suppliers as sponsors or exhibitors.
The main conference room has a biotech investment focus; the technology room features devices, diagnostics, delivery and development tools. One-to-one meetings take place throughout the day. The Exhibition and quiet area double up for lunch service and refreshments are available all day.
One-to-one partnering meetings are pre-booked using the globally-renowned Meeting Mojo booking platform. Registered delegates can log in to browse profiles, set their own availability, request meetings, and promote their company to best advantage.
Networking begins on the evening before the conference with an exclusive Reception in Central London, free of charge to all registered delegates.
Applications for presentation slots are being accepted by emailing firstname.lastname@example.org. DO NOT register here for delegate, sponsor, or exhibitor passes – instead follow the link in your invitation or request an invitation here.
Gold and Partnering Sponsors
Organisations registered to attend include:
65 Investors: 4BIO Capital, Abingworth, Advent Life Sciences, Albion Technology & General VCT, Amadeus Capital Partners, Anvil Partners, Arix Bioscience, Arrowfield Capital, Axilium Capital, Bioscience Managers, BioSeed Capital, Bridge Valley Ventures, Catapult Ventures, Curam Capital Management, DeBere Capital Partners, Deltec International Group, FastVentures, Glentworth Ventures, Hayfin Capital Management, Helsinn Investment Fund, Ignite Capital Partners, Industrifonden, INKEF Capital, Inkef Capital, Innovator Capital, Inventages Venture Capital, Investor Corporat, IPF Partners, JJDC, Julz Co, Longacre Funding partners, LSP, M Ventures, Masselos Family Office, MEDICXI, Mercia Technologies, Molecular Warehouse, Momentum Biotech, MVM Partners, National Institute for Health Research, NCL Technology Ventures, Newable Private Investing, New Science Fund, Norgine Ventures, Novo Seeds, Novo Ventures, NVM, Optum Ventures, Panakes Partners, Rosetta Capital, Rothschild, S.R.One, SBA, Seroba Life Sciences, Seventure, Sofinnova, Start Codon, Sunstone Life Science Ventures, The Cure Parkinson’s Trust, Trillium Medical Ventures, UCL Technology Fund, UKI2S, Velocity Fund Partners, Vivanova.
Delegates: Abbvie, Ablatus Therapeutics, AstraZeneca, Bayer, Eli Lilly, Johnson and Johnson Innovation, Merck, Otsuka Europe, Ablatus Therapeutics, Acesion Pharma, Adenium Biotech, Antagonis, Apitope, Arcus Altor, Arterial Capital Management, Artios Pharma, Asceneuron, Athena Market Access Solutions, AVILLION, BioCentury Publications, BioPartner UK, Biotec Pharmacon, BTG, Calliditas, Censo Biotechnologies, CMR Surgical, COMPASS Pathways, Cumulus Oncology, Department for International Trade, Drug Discovery Today, Embassy of Spain in London, EP Vantage, Eurofins Amatsigroup, Evox Therapeutics, Ezenze, F2G, Fusion Antibodies, Global Regulatory Services, ImaginAB, International Biotechnology Trust, Invest in Denmark, Embassy of Denmark, ISA Therapeutics, J A Kemp, Jefferies, Labiotech.eu, Lavivo, London Business School, LSX, Masters Speciality Pharma, Medherant, Medicon Valley Alliance, MediSieve Limited, Meeting Mojo, Mission Therapeutics, Nature Biotechnology, One Nucleus, Optimum Strategic Communications, Oxford Cardiomox, NMD Pharma, Parkinson’s Concierge, PCI Clinical Services, Pebmond Associates, Pharma Publications, Prophylix, Public Health England, RDP Life Sciences, ReNeuron, River Stone, RTC S.p.A., RYSE Asset Management, Sartar Therapeutics, Scrip, Silicon Valley Bank, SIME Clinical AI, Sygnature Discovery, UK BioIndustry Association (BIA), University of Dundee, VAXIMM, Verdict, Virokine Therapeutics, William Reed, Xenogesis, Zerion.